(0.25%) 5 144.25 points
(0.27%) 38 543 points
(0.35%) 17 908 points
(-0.82%) $83.16
(1.25%) $1.947
(-0.10%) $2 344.90
(0.20%) $27.59
(0.75%) $929.00
(-0.28%) $0.932
(-0.29%) $10.99
(-0.39%) $0.797
(0.85%) $92.66
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.61%
@ $80.96
发出时间: 26 Apr 2024 @ 03:38
回报率: 0.01%
上一信号: Apr 26 - 00:49
上一信号:
回报率: 0.63 %
Live Chart Being Loaded With Signals
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally...
Stats | |
---|---|
今日成交量 | 435 170 |
平均成交量 | 831 755 |
市值 | 11.15B |
EPS | $0 ( 2024-02-13 ) |
下一个收益日期 | ( $0.460 ) 2024-05-02 |
Last Dividend | $0.0500 ( 2024-02-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.92 |
ATR14 | $1.870 (2.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-16 | Laukien Frank H | Sell | 1 404 | Common Stock |
2024-03-04 | Requardt Hermann Fritz | Buy | 10 000 | Common Stock |
2024-03-04 | Requardt Hermann Fritz | Buy | 5 000 | Common Stock |
2024-03-04 | Requardt Hermann Fritz | Sell | 13 772 | Common Stock |
2024-03-04 | Requardt Hermann Fritz | Sell | 1 228 | Common Stock |
INSIDER POWER |
---|
-31.65 |
Last 100 transactions |
Buy: 483 678 | Sell: 1 126 200 |
音量 相关性
Bruker Corp 相关性 - 货币/商品
Bruker Corp 财务报表
Annual | 2023 |
营收: | $2.96B |
毛利润: | $1.52B (51.17 %) |
EPS: | $2.92 |
FY | 2023 |
营收: | $2.96B |
毛利润: | $1.52B (51.17 %) |
EPS: | $2.92 |
FY | 2022 |
营收: | $2.53B |
毛利润: | $1.31B (51.59 %) |
EPS: | $2.00 |
FY | 2022 |
营收: | $2.53B |
毛利润: | $1.31B (51.59 %) |
EPS: | $2.00 |
Financial Reports:
No articles found.
Bruker Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0400 | 2016-03-02 |
Last Dividend | $0.0500 | 2024-02-29 |
Next Dividend | $0 | N/A |
Payout Date | 2024-03-15 | |
Next Payout Date | N/A | |
# dividends | 33 | -- |
Total Paid Out | $1.410 | -- |
Avg. Dividend % Per Year | 0.21% | -- |
Score | 4.59 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.12 | |
Div. Directional Score | 8.92 | -- |
Year | Amount | Yield |
---|---|---|
2016 | $0.160 | 0.68% |
2017 | $0.160 | 0.74% |
2018 | $0.160 | 0.46% |
2019 | $0.160 | 0.55% |
2020 | $0.160 | 0.31% |
2021 | $0.160 | 0.30% |
2022 | $0.200 | 0.25% |
2023 | $0.200 | 0.29% |
2024 | $0.0500 | 0.07% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.144 | 1.500 | 7.12 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.101 | 1.200 | 6.65 | 7.98 | [0 - 0.3] |
returnOnEquityTTM | 0.338 | 1.500 | 7.35 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.0688 | -1.000 | 9.31 | -9.31 | [0 - 1] |
currentRatioTTM | 1.800 | 0.800 | 6.00 | 4.80 | [1 - 3] |
quickRatioTTM | 0.933 | 0.800 | 9.22 | 7.37 | [0.8 - 2.5] |
cashRatioTTM | 0.406 | 1.500 | 8.85 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.303 | -1.500 | 4.94 | -7.42 | [0 - 0.6] |
interestCoverageTTM | -11.98 | 1.000 | -5.55 | -5.55 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.41 | 2.00 | 9.20 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.671 | 2.00 | 9.16 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.936 | -1.500 | 6.26 | -9.38 | [0 - 2.5] |
grossProfitMarginTTM | 0.510 | 1.000 | 4.84 | 4.84 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.149 | 1.000 | 9.02 | 9.02 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.272 | 1.000 | 9.60 | 9.60 | [0.2 - 2] |
assetTurnoverTTM | 0.698 | 0.800 | 8.68 | 6.95 | [0.5 - 2] |
Total Score | 11.71 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 27.58 | 1.000 | 7.32 | 0 | [1 - 100] |
returnOnEquityTTM | 0.338 | 2.50 | 8.30 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.671 | 2.00 | 9.44 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.247 | 1.500 | 3.82 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.41 | 2.00 | 9.20 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.0688 | 1.500 | 9.31 | -9.31 | [0 - 1] |
pegRatioTTM | 0.361 | 1.500 | -0.929 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.118 | 1.000 | 9.55 | 0 | [0.1 - 0.5] |
Total Score | 6.12 |
Bruker Corp
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。